{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T20:06:12Z","timestamp":1772136372557,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T00:00:00Z","timestamp":1731715200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T00:00:00Z","timestamp":1731715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-79781-6","type":"journal-article","created":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T00:50:52Z","timestamp":1731718252000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A multicenter, phase II trial of triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine for highly emetogenic chemotherapy in breast cancer (PATROL-II)"],"prefix":"10.1038","volume":"14","clinical-trial-number":[{"clinical-trial-number":"umin000038644","registry":"10.18810\/umin-japan"}],"author":[{"given":"Kenichi","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9988-128X","authenticated-orcid":false,"given":"Takashi","family":"Yokokawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Takada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Tamaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yohei","family":"Kawasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takumi","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Koizumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuma","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukio","family":"Sakata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Arakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Ayuhara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mari","family":"Hosonaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masakazu","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8894-2841","authenticated-orcid":false,"given":"Daiki","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,16]]},"reference":[{"key":"79781_CR1","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s10147-017-1117-y","volume":"22","author":"H Sasaki","year":"2017","unstructured":"Sasaki, H. et al. Patient perceptions of symptoms and concerns during cancer chemotherapy: \u2018affects my family\u2019 is the most important. Int. J. Clin. Oncol. 22, 793\u2013800. https:\/\/doi.org\/10.1007\/s10147-017-1117-y (2017).","journal-title":"Int. J. Clin. Oncol."},{"key":"79781_CR2","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1007\/s00520-009-0737-9","volume":"18","author":"PJ Hesketh","year":"2010","unstructured":"Hesketh, P. J., Aapro, M., Street, J. C. & Carides, A. D. Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy. Support Care Cancer 18, 1171\u20131177. https:\/\/doi.org\/10.1007\/s00520-009-0737-9 (2010).","journal-title":"Support Care Cancer"},{"key":"79781_CR3","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1093\/annonc\/mdw220","volume":"27","author":"K Suzuki","year":"2016","unstructured":"Suzuki, K. et al. Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study. Ann. Oncol. 27, 1601\u20131606. https:\/\/doi.org\/10.1093\/annonc\/mdw220 (2016).","journal-title":"Ann. Oncol."},{"key":"79781_CR4","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/S1470-2045(19)30678-3","volume":"21","author":"H Hashimoto","year":"2020","unstructured":"Hashimoto, H. et al. Olanzapine 5\u00a0mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 21, 242\u2013249. https:\/\/doi.org\/10.1016\/S1470-2045(19)30678-3 (2020).","journal-title":"Lancet Oncol."},{"key":"79781_CR5","doi-asserted-by":"publisher","first-page":"v119","DOI":"10.1093\/annonc\/mdw270","volume":"27","author":"F Roila","year":"2016","unstructured":"Roila, F. et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann. Oncol. 27, v119\u2013v133. https:\/\/doi.org\/10.1093\/annonc\/mdw270 (2016).","journal-title":"Ann. Oncol."},{"key":"79781_CR6","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1200\/JCO.20.01296","volume":"38","author":"PJ Hesketh","year":"2020","unstructured":"Hesketh, P. J. et al. Antiemetics: ASCO guideline update. J. Clin. Oncol. 38, 2782\u20132797. https:\/\/doi.org\/10.1200\/JCO.20.01296 (2020).","journal-title":"J. Clin. Oncol."},{"key":"79781_CR7","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1634\/theoncologist.2016-0308","volume":"22","author":"M Nakamura","year":"2017","unstructured":"Nakamura, M. et al. A prospective observational study on effect of short-term periodic steroid premedication on bone metabolism in gastrointestinal cancer (ESPRESSO-01). Oncologist 22, 592\u2013600. https:\/\/doi.org\/10.1634\/theoncologist.2016-0308 (2017).","journal-title":"Oncologist"},{"key":"79781_CR8","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/sj.bjc.6603048","volume":"94","author":"J Vardy","year":"2006","unstructured":"Vardy, J. et al. Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br. J. Cancer 94, 1011\u20131015. https:\/\/doi.org\/10.1038\/sj.bjc.6603048 (2006).","journal-title":"Br. J. Cancer"},{"key":"79781_CR9","doi-asserted-by":"publisher","first-page":"210","DOI":"10.12788\/jcso.0256","volume":"14","author":"Y Nakayama","year":"2016","unstructured":"Nakayama, Y., Ito, Y., Tanabe, M. & Takahashi, S. Omission of dexamethasone from antiemetic treatment for highly emetogenic chemotherapy in breast cancer patients with hepatitis B infection or diabetes mellitus. J. Community Support Oncol. 14, 210\u2013214. https:\/\/doi.org\/10.12788\/jcso.0256 (2016).","journal-title":"J. Community Support Oncol."},{"key":"79781_CR10","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s40425-018-0371-5","volume":"6","author":"AJ Giles","year":"2018","unstructured":"Giles, A. J. et al. Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy. J. Immunother Cancer 6, 51. https:\/\/doi.org\/10.1186\/s40425-018-0371-5 (2018).","journal-title":"J. Immunother Cancer"},{"key":"79781_CR11","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1084\/jem.20190738","volume":"216","author":"A Tokunaga","year":"2019","unstructured":"Tokunaga, A. et al. Selective inhibition of low-affinity memory CD8(+) T cells by corticosteroids. J. Exp. Med. 216, 2701\u20132713. https:\/\/doi.org\/10.1084\/jem.20190738 (2019).","journal-title":"J. Exp. Med."},{"key":"79781_CR12","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1200\/JCO.2017.74.4375","volume":"36","author":"Y Ito","year":"2018","unstructured":"Ito, Y. et al. Placebo-controlled, double-blinded phase iii study comparing dexamethasone on day 1 with dexamethasone on days 1 to 3 with combined neurokinin-1 receptor antagonist and palonosetron in high-emetogenic chemotherapy. J. Clin. Oncol. 36, 1000\u20131006. https:\/\/doi.org\/10.1200\/JCO.2017.74.4375 (2018).","journal-title":"J. Clin. Oncol."},{"key":"79781_CR13","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1515725","volume":"375","author":"RM Navari","year":"2016","unstructured":"Navari, R. M. et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N. Engl. J. Med. 375, 134\u2013142. https:\/\/doi.org\/10.1056\/NEJMoa1515725 (2016).","journal-title":"N. Engl. J. Med."},{"key":"79781_CR14","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41416-023-02493-7","volume":"130","author":"H Minatogawa","year":"2024","unstructured":"Minatogawa, H. et al. Dexamethasone-sparing on days 2\u20134 with combined palonosetron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED trial). Br. J. Cancer 130, 224\u2013232. https:\/\/doi.org\/10.1038\/s41416-023-02493-7 (2024).","journal-title":"Br. J. Cancer"},{"key":"79781_CR15","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s10147-015-0786-7","volume":"20","author":"K Tamura","year":"2015","unstructured":"Tamura, K. et al. Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan. Int. J. Clin. Oncol. 20, 855\u2013865. https:\/\/doi.org\/10.1007\/s10147-015-0786-7 (2015).","journal-title":"Int. J. Clin. Oncol."},{"key":"79781_CR16","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1097\/PSY.0000000000000372","volume":"78","author":"D Jung","year":"2016","unstructured":"Jung, D. et al. Longitudinal association of poor sleep quality with chemotherapy-induced nausea and vomiting in patients with breast cancer. Psychosom. Med. 78, 959\u2013965. https:\/\/doi.org\/10.1097\/PSY.0000000000000372 (2016).","journal-title":"Psychosom. Med."},{"key":"79781_CR17","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1177\/1740774520975120","volume":"18","author":"E Basch","year":"2021","unstructured":"Basch, E. et al. Composite grading algorithm for the National Cancer Institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). Clin. Trials 18, 104\u2013114. https:\/\/doi.org\/10.1177\/1740774520975120 (2021).","journal-title":"Clin. Trials"},{"key":"79781_CR18","doi-asserted-by":"publisher","first-page":"4025","DOI":"10.1007\/s00520-016-3203-5","volume":"24","author":"K Kubota","year":"2016","unstructured":"Kubota, K. et al. Control of nausea with palonosetron versus granisetron, both combined with dexamethasone, in patients receiving cisplatin- or anthracycline plus cyclophosphamide-based regimens. Support Care Cancer 24, 4025\u20134033. https:\/\/doi.org\/10.1007\/s00520-016-3203-5 (2016).","journal-title":"Support Care Cancer"},{"key":"79781_CR19","doi-asserted-by":"publisher","first-page":"877","DOI":"10.21873\/anticanres.12297","volume":"38","author":"M Nawa-Nishigaki","year":"2018","unstructured":"Nawa-Nishigaki, M. et al. Control of nausea and vomiting in patients receiving anthracycline\/cyclophosphamide chemotherapy for breast cancer. Anticancer Res. 38, 877\u2013884. https:\/\/doi.org\/10.21873\/anticanres.12297 (2018).","journal-title":"Anticancer Res."},{"key":"79781_CR20","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s41687-017-0022-5","volume":"2","author":"T Kawaguchi","year":"2017","unstructured":"Kawaguchi, T. et al. The Japanese version of the National Cancer Institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE): psychometric validation and discordance between clinician and patient assessments of adverse events. J. Patient Rep. Outcomes 2, 2. https:\/\/doi.org\/10.1186\/s41687-017-0022-5 (2017).","journal-title":"J. Patient Rep. Outcomes"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-79781-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-79781-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-79781-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T06:27:54Z","timestamp":1731997674000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-79781-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,16]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["79781"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-79781-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4832452\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,16]]},"assertion":[{"value":"31 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was conducted in accordance with Ethical Guidelines for Medical and Health Research Involving Human Subjects published by Japan\u2019s Ministry of Education, Culture, Sports, Science and Technology and the Ministry of Health, Labour and Welfare, Japan, and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written, informed consent was obtained from all participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"28271"}}